Group One Trading
ABCL icon

Group One Trading’s AbCellera Biologics ABCL Stock Holding History

Group One Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$650K Sell
82,800
-5,300
-6% -$25.9K ﹤0.01% 3246
2026
Q1 		$307K Buy
88,100
+20,800
+31% +$74.8K ﹤0.01% 3772
2025
Q4 		$230K Sell
67,300
-42,700
-39% -$191K ﹤0.01% 4254
2025
Q3 		$553K Buy
110,000
+75,700
+221% +$334K ﹤0.01% 3611
2025
Q2 		$118K Sell
34,300
-22,900
-40% -$57K ﹤0.01% 4836
2025
Q1 		$128K Buy
57,200
+11,400
+25% +$32.7K ﹤0.01% 4416
2024
Q4 		$134K Buy
45,800
+6,000
+15% +$16.7K ﹤0.01% 4268
2024
Q3 		$103K Buy
39,800
+1,900
+5% +$5.26K ﹤0.01% 4147
2024
Q2 		$112K Buy
37,900
+14,800
+64% +$56K ﹤0.01% 3876
2024
Q1 		$105K Sell
23,100
-3,200
-12% -$16.3K ﹤0.01% 4113
2023
Q4 		$150K Sell
26,300
-72,700
-73% -$337K ﹤0.01% 4124
2023
Q3 		$455K Buy
99,000
+67,300
+212% +$409K ﹤0.01% 3009
2023
Q2 		$205K Buy
31,700
+3,300
+12% +$22.5K ﹤0.01% 3905
2023
Q1 		$214K Sell
28,400
-17,400
-38% -$158K ﹤0.01% 3605
2022
Q4 		$464K Sell
45,800
-68,700
-60% -$794K ﹤0.01% 3109
2022
Q3 		$1.13M Sell
114,500
-2,700
-2% -$29.6K ﹤0.01% 2445
2022
Q2 		$1.25M Buy
117,200
+69,300
+145% +$587K ﹤0.01% 2536
2022
Q1 		$467K Sell
47,900
-158,200
-77% -$1.5M ﹤0.01% 3884
2021
Q4 		$2.95M Buy
206,100
+5,600
+3% +$85K ﹤0.01% 2200
2021
Q3 		$4.02M Buy
200,500
+152,600
+319% +$2.7M ﹤0.01% 1926
2021
Q2 		$1.05M Buy
47,900
+47,500
+11,875% +$1.31M ﹤0.01% 3352
2021
Q1 		$14K Buy
+400
New +$15.9K ﹤0.01% 6895

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Group One Trading's ABCL Position: Q2 2026 in Review

Group One Trading reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $197K and leaving 198,793 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

Group One Trading first reported a position in ABCL in Q2 2021 and has held it in 19 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Group One Trading held 198,793 shares of AbCellera Biologics worth $1.56M as of Q2 2026.
  • Group One Trading sold 40,340 AbCellera Biologics shares in Q2 2026, an estimated $197K.
  • AbCellera Biologics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #2461 holding.
  • Group One Trading first reported a position in AbCellera Biologics in Q2 2021 and has held it in 19 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.